BioCentury | Dec 21, 2015
Clinical News

S48168 regulatory update

...FDA granted rare pediatric disease and Orphan Drug designation to ARM210 from Armgo to treat Duchenne...
...and Japan to develop and commercialize Armgo’s Rycal compounds for cardiovascular and skeletal muscle indications. Armgo Pharma Inc....
BioCentury | Jul 21, 2014
Company News

Intezyne management update

...partner at Deerfield Partners; and Carolyn Paradise as acting CMO, formerly president and COO of Armgo Pharma Inc. WIR...
BioCentury | Sep 20, 2012
Targets & Mechanisms

Stabilizing RyR2

...found that the strategy could be effective for Alzheimer's disease. 1,2 Based on these findings, Armgo Pharma Inc....
...disruptions in calcium homeostasis in conditions ranging from cardiovascular disease to neurodegeneration. 3,4 In 2004, Armgo...
...has patented the use of Rycals for PTSD and has licensed the IP to Armgo. Armgo...
BioCentury | Sep 13, 2012
Distillery Therapeutics

Indication: Neurology

...5(36); doi:10.1038/scibx.2012.960 Published online Sept. 13, 2012 Patent application filed by Columbia University; licensed to Armgo Pharma Inc....
BioCentury | Sep 10, 2012
Clinical News

Armgo preclinical data

...nonstressed controls (p<0.001). S107 is a ryanodine receptor 1 (RyR1) calcium ion release channel stabilizer. Armgo Pharma Inc....
BioCentury | Sep 6, 2012
Distillery Therapeutics

Indication: Neurology

...dantrolene-like compound with higher specificity for RyR1. SpePharm Holding B.V. markets dantrolene to treat hypothermia. Armgo Pharma Inc.'s...
BioCentury | Jan 19, 2012
Distillery Therapeutics

Indication: Other

...to muscle dysfunction and sudden death. Next steps include testing AICAR in large animal models. Armgo Pharma Inc.'s...
BioCentury | Nov 7, 2011
Strategy

Servicing CV

...mAb against IL-1 beta in the U.S. and Japan. In 2007, Servier gained rights to Armgo Pharma Inc....
...a myeloproliferative disorder. Marshall said the program is "nearing IND-enabling studies." Companies and Institutions Mentioned Armgo Pharma Inc....
BioCentury | Aug 29, 2011
Financial News

Armgo completes venture financing

Armgo Pharma Inc. , Tarrytown, N.Y. Business: Cardiovascular, Musculoskeletal Date completed: 8/12/11 Type: Venture financing Raised: $1 million WIR Staff...
BioCentury | May 9, 2011
Company News

Armgo management update

Armgo Pharma Inc. , Tarrytown, N.Y. Business: Cardiovascular, Musculoskeletal Hired: Sapan Shah as CEO and a director, formerly CEO and president at Shionogi & Co. Ltd. 's Shionogi Inc. subsidiary WIR Staff Cardiovascular Musculoskeletal...
Items per page:
1 - 10 of 12
BioCentury | Dec 21, 2015
Clinical News

S48168 regulatory update

...FDA granted rare pediatric disease and Orphan Drug designation to ARM210 from Armgo to treat Duchenne...
...and Japan to develop and commercialize Armgo’s Rycal compounds for cardiovascular and skeletal muscle indications. Armgo Pharma Inc....
BioCentury | Jul 21, 2014
Company News

Intezyne management update

...partner at Deerfield Partners; and Carolyn Paradise as acting CMO, formerly president and COO of Armgo Pharma Inc. WIR...
BioCentury | Sep 20, 2012
Targets & Mechanisms

Stabilizing RyR2

...found that the strategy could be effective for Alzheimer's disease. 1,2 Based on these findings, Armgo Pharma Inc....
...disruptions in calcium homeostasis in conditions ranging from cardiovascular disease to neurodegeneration. 3,4 In 2004, Armgo...
...has patented the use of Rycals for PTSD and has licensed the IP to Armgo. Armgo...
BioCentury | Sep 13, 2012
Distillery Therapeutics

Indication: Neurology

...5(36); doi:10.1038/scibx.2012.960 Published online Sept. 13, 2012 Patent application filed by Columbia University; licensed to Armgo Pharma Inc....
BioCentury | Sep 10, 2012
Clinical News

Armgo preclinical data

...nonstressed controls (p<0.001). S107 is a ryanodine receptor 1 (RyR1) calcium ion release channel stabilizer. Armgo Pharma Inc....
BioCentury | Sep 6, 2012
Distillery Therapeutics

Indication: Neurology

...dantrolene-like compound with higher specificity for RyR1. SpePharm Holding B.V. markets dantrolene to treat hypothermia. Armgo Pharma Inc.'s...
BioCentury | Jan 19, 2012
Distillery Therapeutics

Indication: Other

...to muscle dysfunction and sudden death. Next steps include testing AICAR in large animal models. Armgo Pharma Inc.'s...
BioCentury | Nov 7, 2011
Strategy

Servicing CV

...mAb against IL-1 beta in the U.S. and Japan. In 2007, Servier gained rights to Armgo Pharma Inc....
...a myeloproliferative disorder. Marshall said the program is "nearing IND-enabling studies." Companies and Institutions Mentioned Armgo Pharma Inc....
BioCentury | Aug 29, 2011
Financial News

Armgo completes venture financing

Armgo Pharma Inc. , Tarrytown, N.Y. Business: Cardiovascular, Musculoskeletal Date completed: 8/12/11 Type: Venture financing Raised: $1 million WIR Staff...
BioCentury | May 9, 2011
Company News

Armgo management update

Armgo Pharma Inc. , Tarrytown, N.Y. Business: Cardiovascular, Musculoskeletal Hired: Sapan Shah as CEO and a director, formerly CEO and president at Shionogi & Co. Ltd. 's Shionogi Inc. subsidiary WIR Staff Cardiovascular Musculoskeletal...
Items per page:
1 - 10 of 12